MedTrace Logo

Intra-arterial Versus Systemic Thrombolysis for Acute Ischemic Stroke

NCT00640367 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2014-04-25

No results posted yet for this study

Summary

SYNTHESIS is a pragmatic multicenter randomized controlled trial (RCT), open-label, with blinded follow-up aiming to determine whether loco-regional intra-arterial (IA) with recombinant tissue-plasminogen activator (rt-PA) and/or mechanical devices, as compared with systemic intravenous (I.V.) infusion of rt-PA within 3 hours of ischemic stroke, increases the proportion of independent survivors at 3 months.

Conditions

  • Stroke
  • Cerebrovascular Accident

Interventions

OTHER

Alteplase IA and/or mechanical thrombolysis

loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis

DRUG

Alteplase IV

intravenous recombinant tissue plasminogen activator

Sponsors & Collaborators

  • Niguarda Hospital

    lead OTHER

Principal Investigators

  • Alfonso Ciccone, MD · A.O. Ospedale Niguarda Ca' Granda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-02-28
Completion
2012-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00640367 on ClinicalTrials.gov